Dina is a Partner with NeoMed Management, having joined the firm in 2009. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001, having previously worked at 3i in London and Index Ventures in Geneva. Her recent investments include Oxular, Wilson Therapeutics, Endosense, EUSA Pharma and Novexel. She is a director on the board of Oxular and Wilson Therapeutics and has previously served on the Boards of Endosense and Microsulis. Dina is a CFA charterholder and holds a PhD degree in Molecular and Cellular Biology from Paris VI University, France. She carried out postdoctoral research at Brown University, US and at the Fox Chase Cancer Centre, US. Dina is a Partner with NeoMed Management, having joined the firm in 2009. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001, having previously worked at 3i in London and Index Ventures in Geneva. Her recent investments include Oxular, Wilson Therapeutics, Endosense, EUSA Pharma and Novexel. She is a director on the board of Oxular and Wilson Therapeutics and has previously served on the Boards of Endosense and Microsulis. Dina is a CFA charterholder and holds a PhD degree in Molecular and Cellular Biology from Paris VI University, France. She carried out postdoctoral research at Brown University, US and at the Fox Chase Cancer Centre, US.

fermentation